{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:49:49Z","timestamp":1789778989855,"version":"4.0.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"abstract":"\n Background:<\/jats:title>\n Polycystic ovary syndrome (PCOS) is one of the common endocrine disorders in women of reproductive ages. It is associated with a range of disorders, such as dyslipidemia, hypertension, insulin resistance (IR), compensatory hyperinsulinemia, gestational, and type 2 diabetes, and increased risk of cardiovascular morbidity. There are different treatments available for PCOS. The purpose of this study was to determine and compare the effects of metformin, flutamide plus oral contraceptives (OCs), and simvastatin on the metabolic consequences of PCOS.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n \n This study was a single-blind clinical trial. The subjects were selected from a group of patient with PCOS and metabolic syndrome, who were referred to the midwifery clinic of Al-Zahra Hospital and Beheshti Hospital, Isfahan, Iran. A total of 111 subjects were randomly assigned to three groups: metformin, flutamide plus OCs, and simvastatin groups. The measurements were performed at baseline and after 6 months of therapy. Paired\n t<\/jats:italic>\n -test, analysis of variance (ANOVA), and chi-square test were applied in this study.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n A total of 102 subjects were analyzed in this study, 34 subjects were allotted in each group. The prevalence of IR was statistically different between three groups (\n P<\/jats:italic>\n -value = 0.001). After a 6-month course, metformin showed larger reduction in fasting blood sugar (FBS) level (\n P<\/jats:italic>\n -value < 0.001). However, except for metformin, two other treatments reduced C-reactive protein (CRP) level significantly (both\n P<\/jats:italic>\n -values < 0.001). The level of triglycerides (TGs) decreased considerably in all groups (all\n P<\/jats:italic>\n -values < 0.001). Both metformin and simvastatin decreased BMI significantly (both\n P<\/jats:italic>\n -values < 0.001). None of the treatments changed high-density lipoprotein (HDL) level (all\n P<\/jats:italic>\n -values > 0.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Metformin performed better in FBS reduction. Simvastatin had better performance in terms of reducing TG level and waist circumference.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/1735-1995.177354","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T00:08:16Z","timestamp":1470355696000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome"],"prefix":"10.4103","volume":"21","author":[{"given":"Ferdous","family":"Mehrabian","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatav","family":"Ghasemi-Tehrani","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboobe","family":"Mohamadkhani","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Moeinoddini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooya","family":"Karimzadeh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,2,23]]},"reference":[{"key":"R1-20250827","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1210\/jc.2011-0501","article-title":"Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment","volume":"96","author":"Banaszewska","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R2-20250827","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrendo.2010.217","article-title":"Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis","volume":"7","author":"Goodarzi","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"R3-20250827","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-14-0253","article-title":"; ESE PCOS Special Interest Group. The polycystic ovary syndrome: A position statement from the European Society of Endocrinology","volume":"171","author":"Conway","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"R4-20250827","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1210\/jc.2006-1988","article-title":"Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: Prospective, randomized, crossover trial","volume":"92","author":"Banaszewska","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-20250827","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2011-3061","article-title":"Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): A multicenter, double-blind, placebo-controlled randomized trial","volume":"97","author":"Morin-Papunen","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-20250827","first-page":"4047","article-title":"Polycystic ovarian syndrome: Evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone 1","volume":"85","author":"Eagleson","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-20250827","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.amjmed.2014.04.017","article-title":"Polycystic ovary syndrome: Update on diagnosis and treatment","volume":"127","author":"Setji","year":"2014","journal-title":"Am J Med"},{"key":"R8-20250827","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/2042018812437355","article-title":"The effects of old, new and emerging medicines on metabolic aberrations in PCOS","volume":"3","author":"Bargiota","year":"2012","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R9-20250827","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2174\/138161212799040457","article-title":"Phenotypes and environmental factors: Their influence in PCOS","volume":"18","author":"Diamanti-Kandarakis","year":"2012","journal-title":"Curr Pharm Des"},{"key":"R10-20250827","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005552.pub2","article-title":"Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome","author":"Costello","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-20250827","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1345\/aph.1Q514","article-title":"Polycystic ovary syndrome and chronic inflammation: Pharmacotherapeutic implications","volume":"46","author":"Sirmans","year":"2012","journal-title":"Ann Pharmacother"},{"key":"R12-20250827","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/1479164109336050","article-title":"Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome","volume":"6","author":"Cheang","year":"2009","journal-title":"Diab Vasc Dis Res"},{"key":"R13-20250827","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/EJE-07-0133","article-title":"Metformin administration improves leukocyte count in women with polycystic ovary syndrome: A 6-month prospective study","volume":"157","author":"Orio","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"R14-20250827","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.fertnstert.2009.11.045","article-title":"Effects of metformin plus simvastatin on polycystic ovary syndrome: A prospective, randomized, double-blind, placebo-controlled study","volume":"94","author":"Kazerooni","year":"2010","journal-title":"Fertil Steril"},{"key":"R15-20250827","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/humrep\/del407","article-title":"Polycystic ovary syndrome, oral contraceptives and metabolic issues: New perspectives and a unifying hypothesis","volume":"22","author":"Nader","year":"2007","journal-title":"Hum Reprod"},{"key":"R16-20250827","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2042018810367984","article-title":"Evidence for statin therapy in polycystic ovary syndrome","volume":"1","author":"Sathyapalan","year":"2010","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R17-20250827","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/EJE-09-0733","article-title":"Metformin: An old medication of new fashion: Evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome","volume":"162","author":"Diamanti-Kandarakis","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"R18-20250827","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: An endocrine society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-20250827","first-page":"2","article-title":"The effect of adding simvastatin or metformin to Yasmin\u00ae on the endocrine and metabolic parameters in polycystic ovarian syndrome","volume":"4","author":"Lim","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-20250827","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1530\/EJE-07-0261","article-title":"Flutamide metformin for post-menarcheal girls with preclinical ovarian androgen excess: Evidence for differential response by androgen receptor genotype","volume":"157","author":"Ong","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"R21-20250827","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"R22-20250827","first-page":"763","article-title":"The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females","volume":"16","author":"Mehrabian","year":"2011","journal-title":"J Res Med Sci"},{"key":"R23-20250827","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1055\/s-0029-1220770","article-title":"Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study","volume":"118","author":"Kaya","year":"2010","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"R24-20250827","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1210\/jc.2008-1750","article-title":"The effect of atorvastatin in patients with polycystic ovary syndrome: A randomized double-blind placebo-controlled study","volume":"94","author":"Sathyapalan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R25-20250827","first-page":"139","article-title":"Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation 1","volume":"85","author":"Moghetti","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R26-20250827","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","article-title":"Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy","volume":"43","author":"Velazquez","year":"1994","journal-title":"Metabolism"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01222967-201621000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:25:05Z","timestamp":1787837105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01222967-201621000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/1735-1995.177354","relation":{},"ISSN":["1735-1995","1735-7136"],"issn-type":[{"value":"1735-1995","type":"print"},{"value":"1735-7136","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"2015-06-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}